iPharmag Integrated Pharma Magazine
Conceptual illustration of a KRAS G12C inhibitor binding its target protein
Regulatory

FDA Grants Breakthrough Status to Lilly’s Olomorasib in KRAS-Mutant Pancreatic Cancer

KRAS is mutated in 90% of pancreatic cancers. This drug addresses the 1–2% with the one subtype chemistry has learned to hit.

Latest news